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Abstract
Aims/hypothesis Glucose-dependent insulinotropic poly-
peptide (GIP) is an enteroendocrine hormone that pro-
motes storage of glucose and fat. Its secretion from
intestinal K cells is triggered by nutrient ingestion and
is modulated by intracellular cAMP. In view of the
proadipogenic actions of GIP, this study aimed to iden-
tify pathways in K cells that lower cAMP levels and
GIP secretion.
Methods Murine K cells purified by flow cytometry were
analysed for expression of Gαi-coupled receptors by
transcriptomic microarrays. Somatostatin and cannabi-
noid receptor expression was confirmed by quantitative
RT-PCR. Hormone secretion in vitro was measured in
GLUTag and primary murine intestinal cultures. cAMP was
monitored in GLUTag cells using the genetically encoded
sensor Epac2-camps. In vivo tolerance tests were performed
in cannulated rats.
Results Purified murine K cells expressed high mRNA lev-
els for somatostatin receptors (Sstrs) Sstr2, Sstr3 and Sstr5,
and cannabinoid receptor type 1 (Cnr1, CB1). Somatostatin
inhibited GIP and glucagon-like peptide-1 (GLP-1) secre-
tion from primary small intestinal cultures, in part through
SSTR5, and reduced cAMP generation in GLUTag cells.
Although the CB1 agonist methanandamide (mAEA)
inhibited GIP secretion, no significant effect was ob-
served on GLP-1 secretion from primary cultures. In
cannulated rats, treatment with mAEA prior to an oral
glucose tolerance test suppressed plasma GIP but not GLP-1
levels, whereas the CB1 antagonist AM251 elevated basal
GIP concentrations.
Conclusions/interpretation GIP release is inhibited by
somatostatin and CB1 agonists. The differential effects
of CB1 ligands on GIP and GLP-1 release may provide
a new tool to dissociate secretion of these incretin
hormones and lower GIP but not GLP-1 levels in vivo.
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Abbreviations
CB1 Cannabinoid receptor type 1
CFP Cyan fluorescent protein
CNS Central nervous system
Ct Cycle threshold
FRET Förster resonance energy transfer
GIP Glucose-dependent insulinotropic polypeptide
GLP-1 Glucagon-like peptide-1
IBMX Isobutylmethylxanthine
mAEA Methanandamide
RMA Robust multichip average
SGLT1 Sodium-dependent glucose transporter 1
SSTR Somatostatin receptor
SSTR5A SSTR5 antagonist
YFP Yellow fluorescent protein
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Introduction
Glucose-dependent insulinotropic polypeptide (GIP) is a
hormone from the proximal small intestine that is secreted
in response to food ingestion [1]. Although it acts as an
incretin hormone to promote insulin secretion, mice lacking
GIP receptors show only a mild impairment of postprandial
glucose homeostasis [2], but appear to be protected from the
obesogenic effects of either a high-fat diet or the hyperphagic
leptin deficient ob/ob background [3]. Similar amelioration of
diet-induced obesity, with correspondingly improved insulin
sensitivity, was observed in other mouse models with im-
paired GIP signalling due to treatment with a GIP-receptor
antagonist (Pro3-GIP) [4] or ablation of GIP-secreting K cells
[5]. These results have been used to argue that inhibiting GIP
signallingmay have beneficial effects in obese individuals [6].
A similar outcome could potentially be achieved by reducing
GIP secretion.
GIP release is triggered by the arrival of nutrients in the
upper small intestine, where it is produced by enteroendocrine
K cells located predominantly in the duodenal epithelium [1].
These are an open-type endocrine cell, with apical surfaces
facing into the gut lumen, capable of directly sampling the
luminal contents [7, 8]. They are stimulated by a variety of
nutrients, including monosaccharides and fats [1, 9]. Glucose
sensing involves uptake by the sodium-dependent glucose
cotransporter 1 (SGLT1), a sodium-coupled transporter, as
exemplified by the loss of glucose-triggered GIP secretion in
SGLT1-deficient mice [10]. The electrogenic SGLT1 signal,
however, operates synergistically with cytosolic cAMP levels
[11], providing opportunities for G-protein-coupled receptor
pathways to influence GIP release. The expression of the Gαs-
coupled receptor Gpr119 in K cells, for example, may con-
tribute to fat-dependent GIP secretion via the locally generated
ligands 2-mono-oleoyl glycerol and oleoylethanolamide, pro-
duced by luminal triacylglycerol digestion and local tissue
metabolism, respectively [12, 13]. Relatively little is known
about inhibitory signals that reduce cAMP levels in K cells,
mediated by Gαi-coupled receptors.
Transgenic mice producing the yellow fluorescent pro-
tein (YFP) Venus under the control of the GIP promoter
have provided a new tool for identifying and purifying
K cells for transcriptomic and functional analysis [11]. Here
we report that the expression of Sstr5 and the cannabinoid
receptor type 1 (Cnr1, CB1), examples of predominantly
Gαi-coupled receptors, is enriched in K cells and that these
receptors can be targeted to manipulate GIP secretion.
Methods
Animal models Animal procedures were approved by the
local ethics committee and conformed to UK Home Office
regulations. All mice used in the experiments were on a
C57BL/6 background and housed in individually ventilated
cages. Male Sprague Dawley rats were purchased from Charles
River (Margate, UK) and housed in conventional caging.
Expression analysis K and L cells were isolated by FACS
from GIP-Venus [11] and GLU-Venus [14] transgenic mice,
respectively, as previously described. Briefly, small intestine
(upper 10 cm) or colon was digested as described below for
primary cultures, but using a higher collagenase concentration
of 1 mg/ml in Hank’s buffered salt solution (HBSS), to obtain
single cells. Cell suspensions were separated using a MoFlo
Cytomation sorter (Beckman Coulter, High Wycombe, UK)
(488 nm excitation) to obtain populations of Venus-positive or
Venus-negative cells, which were collected directly into lysis
buffer for mRNA extraction. Purified K and L cell populations
were over 95% pure as assessed by fluorescence microscopy,
and were enriched more than 2,000-fold for GIP and glucagon-
like peptide-1 (GLP-1) concentrations, respectively, compared
with non-fluorescent cells, as assessed by ELISA [11, 14].
RNAwas extracted using a microscale RNA isolation kit
(Applied Biosystems, Warrington, UK) as previously de-
scribed [11, 14]. GLUTag cell RNA was isolated using
TRI reagent. For hybridisation to mouse 430 2.0 arrays
GeneChips (Affymetrix UK, High Wycombe, UK), RNA
underwent two rounds of amplification based on in vitro
translation from a T7 promoter introduced during oligo
dT-priming (Two-cycles cDNA Synthesis Kit, Affymetrix
UK; MEGAscript T7 kit, Ambion, Austin, TX, USA), and
expression levels of each probe were determined by robust
multichip average (RMA) analysis. Quantitative PCR was
performed with cDNA reverse-transcribed from non-
amplified RNA on a 7900 HT Fast Real-Time PCR system
(Applied Biosystems, Foster City, CA, USA) using a Quanti-
Tect SYBR Green PCR mix (Qiagen, Crawley, UK) and the
primers given in Table 1.
In all cases, expression was compared with that of
β-actin measured on the same sample in parallel on the
same plate, giving a cycle threshold (Ct) difference (ΔCt)
for β-actin minus the test gene. Cts for β-actin ranged from
20 to 25 in the different samples, and reactions in which the
test gene was undetectable were assigned a Ct value of 40. A
ΔCt value of −12 to −15 is, therefore, close to the detection
limit of the assay. Mean, SEM and statistics were performed
on the ΔCt data and only converted to relative expression
levels (2ΔCt ) for presentation in the figures.
Primary murine intestinal cultures Mice aged 2–6 months
were killed by cervical dislocation and the guts collected
into ice-cold Leibovitz-15 (L-15) medium (PAA, Yeovil,
UK). Mixed intestinal cultures were produced, as previously
described [11, 14]. Briefly, the intestine was opened longi-
tudinally, rinsed in PBS and chopped into 1–2 mm pieces.
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Upper small intestinal cultures were derived from 10–
15 cm of intestine immediately distal to the stomach,
and colon cultures included tissue distal to the caecum.
Tissue was digested three or four times with 0.4 mg/ml
collagenase XI, centrifuged at 300 g, and resuspended
in DMEM (25 mmol/l glucose) supplemented with 10%
(vol/vol) FBS, 2 mmol/l L-glutamine, 100 units/ml pen-
icillin and 0.1 mg/ml streptomycin. Cell/crypt suspensions
were plated onto 24-well plates coated with a thin film of
Matrigel (BD Bioscience, Oxford, UK) and incubated at 37°C
in 5% CO2.
Cell line culture GLUTag cells were cultured in DMEM
(5.6 mmol/l glucose) supplemented with 10% (vol/vol)
FBS, 2 mmol/l L-glutamine, 100 units/ml penicillin and
0.1 mg/ml streptomycin, at 37°C in 5% CO2.
Secretion studies Around 20–24 h after cell plating, wells
were washed thoroughly with bath solution before being
incubated for 2 h at 37°C with test reagents in bath solution
supplemented with 0.1% BSA. Five hundred KIU/ml apro-
tinin, 10 μmol/l amastatin and 0.1 mmol/l diprotin A were
added to wells planned for GLP-1 assay. The supernatants
were collected and briefly centrifuged before measuring
the hormone content. Primary cultures were subsequently
treated with lysis buffer containing 50 mmol/l Tris-HCl,
150 mmol/l NaCl, 1% IGEPAL-CA 630, 0.5% deoxycholic
acid and one tablet of complete EDTA-free protease inhibitor
cocktail (Roche Dignostics, Burgess Hill, UK). Cells were
mechanically disrupted to extract intracellular peptides.
GLP-1, GIP and/or somatostatin were assayed in supernatant
fractions and cell extracts from primary intestinal cultures, and
in supernatant fractions from GLUTag cells by ELISA
(GLP-1 active ELISA kit, GIP Total ELISA kit, Millipore,
USA; Somatostatin ELISA Kit, Phoenix Pharmaceuticals,
Burlingame, CA, USA).
Hormone secretion from primary cultures was expressed
as a fraction of the total hormone measured in each well and
normalised to the basal secretion measured in parallel on the
same day. Rates of hormone secretion from primary cultures
under basal conditions were 5.1±0.7 pg well−1 2 h−1
(GIP, n047), 1.7±0.1 fmol well−1 2 h−1 (GLP-1 from small
intestinal cultures, n037) and 3.9±0.6 fmol well−1 2 h−1
(GLP-1 from colonic cultures, n09), which was equivalent
to 2.2±0.2%, 6.3±0.4% and 3.0±0.3% of the content being
released in 2 h, respectively. Secretion from GLUTag cells
was normalised to control wells from the same plate. Each
condition was tested in three or four wells per 24-well plate,
so the number of individual experiments can be estimated
by dividing the numbers above the bars by 3 or 4.
cAMP Förster resonance energy transfer measurements
Single-cell measurements of cAMP levels were made using
the Förster resonance energy transfer (FRET)-based sen-
sor Epac2-camps [15]. GLUTag cells were seeded in
6 cm Matrigel-coated plastic dishes and, when 80–90%
confluent, were transfected with 3 μg Epac2-camps DNA
probe and 15 μl Lipofectamine 2000 (Invitrogen, Paisley,
UK) for 24 h. Cells were trypsinised and re-seeded onto
Matrigel-coated 35 mm glass-bottomed dishes (Mattek
Corporation, Ashland, MA, USA) for experiments 24–
48 h later.
Cells, continuously perfused with bath solution supple-
mented with 0.1% BSA with or without test reagents,
were visualised with a ×40 oil immersion objective on
an inverted microscope (Olympus IX71, Southend on Sea,
UK). Excitation at 435 nm was achieved using a xenon
arc lamp coupled to a monochromator (Cairn Research,
Faversham, UK) controlled by MetaFluor software (Mo-
lecular Devices, Wokingham, UK). Cyan fluorescent pro-
tein (CFP) emission at 470 nm and YFP emission at
535 nm were monitored using an Optosplit II beam split-
ter (Cairn Research) and an Orca-ER digital camera
(Hamamatsu, Welwyn Garden City, UK), and expressed
as the CFP/YFP fluorescence ratio [16]. Maximum ratios
were determined at baseline and following test reagent
application, and calculated increments were normalised
to that triggered by the first forskolin application. No
significant differences in the response (by ANOVA) were
observed with recurrent forskolin applications.
Oral glucose tolerance test Male Sprague Dawley rats
(Charles River, Margate, UK) underwent surgical place-
ment of a single right jugular vein catheter as previously
described [17], and were allowed to recover for 4–5 days.
Only animals that had regained their preoperative body
weight with no signs of infection were allowed to pro-
ceed to the study. On the day of study, overnight-fasted
rats were acclimatised to the study room and caging for
Table 1 Amplicon length and sequences of primers used in SYBR
green analysis
Gene Amplicon
length
Primer sequence 5′–3′
CNR1 166 bp fwd: GAGCAAGGACCTGAGACATGC
rev: CTTAACAGTGCTCTTGATGCAGC
CNR2 150 bp Mm_Cnr2_1_SG
SSTR2 150 bp Mm_Sstr2_2_SG
SSTR3 223 bp fwd: ATGGCCACTGTTACCTATCCTTC
rev: GGATATAGACACTGGTCACTGATGG
SSTR5 442 bp fwd: GTCACTAGTGGACCCGGTG
rev: AGAGCGGCAGAGACATGAG
Actb 149 bp Mm_Actb_1_SG
Where the sequence is unknown the product number of the QuantiTect
primer assay is given
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an hour prior to experimentation. A total of 30 min
before the OGTT, rats in the methanandamide (mAEA)
study were dosed intraperitoneally with either mAEA (at
a dose of 10 mg/kg, as previously described [18]) sus-
pended in Tocrisolve (1 ml/kg) or an equal volume of
Tocrisolve alone. In the AM251 study, rats were dosed
intraperitoneally with either vehicle control (lacking only
AM251) or 4 mg/kg of the CB1 antagonist AM251 made
up in DMSO, and dissolved in Tween 80 and normal
saline in a 1:1:8 ratio, with an injection volume of 1 ml/kg
[19]. An oral gavage of 2 g/kg glucose and 100 mg/kg acet-
aminophen dissolved in PBS (10 ml/kg) was administered at
t00. Blood samples of 0.5 ml were taken at −30, 0, 5, 15
and 30 min after gavage. Blood was collected into tubes
containing 4 μl EDTA and immediately spun for 90 s.
Plasma glucose was analysed by Analox GM9 (Analox
Instruments, London, UK); samples for GIP, GLP-1, insu-
lin and acetaminophen were snap-frozen for later analysis.
Plasma GIP was measured by ELISA (GIP Total ELISA
Kit; Millipore, Watford, UK), total GLP-1 and insulin
by immunoassay (MesoScale Discovery, Gaithersburg, MD,
USA), and acetaminophen by colorimetric detection of
p-aminophenol (Siemens, Camberley, UK). Rats were
killed by overdose of anaesthesia immediately after the
30 min sample had been taken.
Solutions and chemicals The bath solution contained (in
mmol/l) 138 NaCl, 4.5 KCl, 4.2 NaHCO3, 1.2 NaH2PO4,
2.6 CaCl2, 1.2 MgCl2, 10 HEPES, 10 glucose. Unless
stated, all drugs and chemicals were obtained from Sigma
(Poole, UK) and, where possible, drugs were made up as
1,000× stock. The mAEA (Tocris, Bristol, UK) was dis-
solved in ethanol for in vitro and Tocrisolve (Tocris) for in
vivo studies. Somatostatin-14 was dissolved in water.
AM251 (Tocris) and the SSTR5 antagonist, referred to as
SSTR5A (Compound A described in [20]; a kind gift from
F. Hoffmann-La Roche AG, Basel, Switzerland) were dis-
solved in DMSO.
Data analysis Comparisons between conditions were made
using Student’s t test (Microsoft Excel) or by one or two-way
ANOVAwith post hoc Bonferroni test (Prism5, GraphPad, La
Jolla, CA, USA), with a threshold for significance of p<0.05.
All data are expressed as mean ± SEM.
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Fig. 1 Enteroendocrine cells express Sstr2, Sstr 3 and Sstr 5. (a) Mean
microarray RMA intensities for probes against Sstr1–Sstr5 in K cells (K+,
black bars), small intestinal and colonic L cells (L+, dark grey bars; LC+,
light grey bars, respectively) and non-fluorescent control cells from the same
tissue preparations (K–, diagonal hatching; L–, horizontal hatching; LC–,
vertical hatching) (n02–3 each). (b–d) Relative expression of Sstr2 (b),
Sstr3 (c) and Sstr5 (d) mRNA relative to β-actin assessed by RT-PCR in
FACS-sorted cell populations labelled as in (a) plus GLUTag cells (white
bars). Data are presented as the geometric mean and upper SEM (n>3 each).
Significance comparisons between K+ and K– , L+ and L–, and K+ and L+
cells were calculated by one-way ANOVA with post hoc Bonferroni test
performed on the log(base 2) data: **p<0.01, ***p<0.001
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Results
Expression of Sstr3 and Sstr5 mRNA is enriched in
K cells To identify Gαi-coupled receptors expressed in
incretin-secreting cells, FACS-purified K and L cells from
GIP-Venus and GLU-Venus mice, respectively, together
with control (non-fluorescent) cells were analysed by
microarray. Consistent with the previously observed inhi-
bition of GIP secretion by somatostatin [21], we detected
signals for Sstr2, Sstr3 and Sstr5 in enteroendocrine cell
populations (Fig. 1a). Quantitative PCR using non-
amplified mRNA from additional FACS-sorted cells simi-
larly showed enrichment of Sstr3 and Sstr5 in enteroendo-
crine cell populations (Fig. 1b). Sstr5, but not Sstr3,
expression was also observed in the colon-derived L cell
model line GLUTag.
Somatostatin inhibits cAMP elevation partially through
SSTR5 activation As SSTRs are believed to couple predom-
inantly via Gαi, we aimed to confirm an effect of SSTR
activation on intracellular cAMP levels. Repeated applica-
tions of forskolin (2 μmol/l) to GLUTag cells resulted in
acute elevations of cytosolic cAMP, as monitored in single
cells producing an Epac-based FRET sensor [16]. Concomi-
tant application of somatostatin resulted in a profound and
reversible suppression of the forskolin-triggered cAMP re-
sponse (Fig. 2a), which was partially reversed by co-
application of a selective SSTR5 antagonist, SSTR5A
(Fig. 2b).
SSTR5 underlies somatostatin-dependent inhibition of GIP
and GLP-1 secretion in primary culture GIP secretion
from K cells in mixed primary small intestinal cultures was
stimulated 2.5±0.3-fold by incubation with the non-specific
phosphodiesterase inhibitor isobutylmethylxanthine (IBMX;
100 μmol/l), presumably reflecting an increase in the cytosol-
ic cAMP concentration. Under these conditions, IBMX-
stimulated GIP secretion was strongly inhibited by co-
application of somatostatin (100 nmol/l) (Fig. 3a). This effect
was significantly, although not completely, reversed by
SSTR5A (100 nmol/l). Neither somatostatin nor SSTR5A
significantly affected GIP secretion under basal conditions in
the absence of IBMX (Fig. 3a). Somatostatin (100 nmol/l)
similarly abolished IBMX-stimulated GLP-1 secretion in
both small and large intestinal cultures (Fig. 3b, c).
SSTR5A reversed the inhibitory effect of somatostatin
on small intestinal GLP-1 release, and also increased
IBMX-triggered secretion in the absence of added somatostat-
in, suggesting the presence of a basal somatostatin tone that is
likely to be due to the presence of somatostatin-secreting
D cells in these mixed intestinal cultures (Fig. 3b). Indeed,
measured somatostatin levels in control wells were 43±13
pmol/l (n07).
High expression of the endocannabinoid receptor Cnr1 in
K cells Mining the microarray data for other Gαi-coupled
receptors, we observed high expression in K cells but not
controls for the probe against Cnr1 (encoding the endocanna-
binoid receptor CB1) (Fig. 4a). This was also detected in small
intestinal, but not colonic, L cells (Fig. 4a). Very little expres-
sion was observed for Cnr2, encoding the related cannabinoid
receptor CB2. By quantitative RT-PCR (Fig. 4b, c), Cnr1
but not Cnr2 expression was similarly found to be enriched
in small intestinal K and L cells, but appeared to be absent
from colonic L cells. Although Cnr1 expression appeared
higher in K than L cells, this did not reach statistical
significance.
CB1 receptor activation inhibits GIP but not GLP-1 secretion
in vitro To assess the functional expression of CB1, we
tested the effect of the CB1 receptor agonist mAEA
(10 μmol/l) on basal and IBMX-stimulated GIP release in
primary small intestinal cultures. mAEA did not affect basal
GIP release but strongly inhibited secretion triggered by
IBMX (Fig. 5a). This effect of mAEAwas significantly atten-
uated by the concomitant presence of the CB1-specific inverse
agonist AM251 (1μmol/l). AM251 alone did not significantly
increase basal or IBMX-stimulated GIP secretion. As Cnr1
was also detected in small intestinal L cells, we assessed
whether mAEA inhibited GLP-1 secretion in primary cultures
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Fig. 2 Somatostatin (Sst) lowers cAMP in the GLUTag cell line.
(a) Changes in cAMP concentration in response to Gαi activation.
GLUTag cells transfected with Epac2-camps were perfused with
forskolin (fsk; 2 μmol/l) with/without Sst (100 nmol/l), followed by
fsk/IBMX (10 and 100 μmol/l respectively) as indicated. CFP and YFP
emission was monitored in response to excitation with 435/10 nm. Three
traces, each representing the CFP/YFP ratio of a single cell, are shown.
(b) Mean changes in the CFP/YFP emission ratio in response to applica-
tion of forskolin (2 μmol/l), Sst (100 nmol/l) or SSTR5A (100 nmol/l) in
experiments performed as in (a). Responses to fsk/Sst, fsk/Sst/SSTR5A
and the final application of fsk alone were normalised to the response
triggered by the first application of fsk in the same cell. Data are means
and error bars show 1 SEM, with the number of cells (monitored in
between five and seven independent experiments per condition) indicated
above each bar. Statistical significance was assessed by one-wayANOVA
with post hoc Bonferroni test: ***p<0.001 compared with first applica-
tion of fsk and ††p<0.01 comparing the Sst response in the absence/
presence of SSTR5A
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from the small intestine and colon. Contrary to the observed
expression of Cnr1 in small intestinal L cells, we observed no
effect of the CB1 ligands on IBMX-stimulated GLP-1 secre-
tion from the small intestine (Fig. 5b, c). GLP-1 secretion from
colonic cultures was also not affected by mAEA or AM251.
Although no effect of mAEA was found on GLP-1 se-
cretion from L cells in primary culture, GLUTag cells were
tested as a potential cell line model for investigating the
effects of CB1 ligands on cAMP levels, as they expressed
mRNA for Cnr1 (see Fig. 4b). Partial inhibition of IBMX-
stimulated GLP-1 secretion by mAEA was observed in
GLUTag cells, which was sensitive to AM251 (Fig. 5d).
Recordings using Epac2-camps (Fig. 5e, f) showed that
mAEA resulted in a small but significant reduction in
forskolin-triggered cAMP responses, which did not reverse
on washout. Co-application of AM251 prevented the effect
of mAEA, supporting the idea that this represents a CB1-
mediated effect.
Effects of CB1 ligands on incretin hormone secretion in
vivo Finally, we assessed whether mAEA or AM251 could
modulate basal or glucose-triggered GIP secretion in vivo.
mAEA orAM251 (or vehicle controls) was administered intra-
peritoneally to fasted rats, and after taking blood samples a
glucose bolus (dose) was given by gavage 30 min later. In the
fasting state, GIP levels were not significantly altered by
mAEA (Fig. 6a) or either of the vehicle controls (DMSO or
Tocrisolve; Fig. 6b), but were increased from 34±4 to
39±4 pmol/l by AM251 (Fig. 6c; p00.04), suggesting that
basal GIP secretion is suppressed by an inhibitory cannabinoid
tone. Basal GLP-1 concentrations were not affected bymAEA,
AM251 or vehicle controls. Following the glucose gavage,
mAEA resulted in lower plasma GIP levels (Fig. 6d,e), but
did not affect concentrations of GLP-1, insulin or glucose
(Fig. 6f–i). Acetaminophen, which was included in the orally
administered glucose solution to monitor gastric emptying, did
not appear with a significantly different time course in the
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Fig. 3 Inhibition of IBMX-stimulated GIP and GLP-1 secretion by
somatostatin (Sst). (a) GIP secretion from primary small intestinal
cultures treated with IBMX (100 μmol/l) with/without Sst (100 nmol/l)
and SSTR5A (100 nmol/l), as indicated. (b,c) GLP-1 secretion from
primary small intestinal (b) and colonic (c) cultures treated with IBMX
(100 μmol/l) with or without Sst (100 nmol/l) and SSTR5A (100 nmol/l),
as indicated. Data are expressed relative to the basal secretory rate
measured in parallel on the same day. Data are means ± SEM of the
number of wells indicated above each bar. Statistical significance was
assessed by one-way ANOVAwith post hoc Bonferroni test: **p<0.01,
***p<0.001 compared with control; †p<0.05, ††p<0.01, †††p<0.001
between conditions as indicated
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Fig. 4 Expression of endocannabinoid receptors in enteroendocrine
cells. (a) Mean microarray RMA intensities for probes against Cnr1
and Cnr2 in K cells (K+, black bars), small intestinal and colonic
L cells (L+, dark grey bars; LC+, light grey bars, respectively), and
non-fluorescent control cells from the same tissue preparations
(K–, diagonal hatching; L–, horizontal hatching; LC–, vertical hatch-
ing) (n02–3 each). (b,c) Relative expression of Cnr1 (b) andCnr2 (c)
mRNA relative to β-actin assessed by RT-PCR in FACS-sorted cell
populations labelled as in (a), together with GLUTag cells (white bar).
Data are presented as the geometric mean and upper SEM (n>3 each).
Significance comparisons between K+ and K– , L+ and L–, and K+
and L+ cells were calculated by one-way ANOVA with post hoc
Bonferroni test performed on the log(base 2) data: ***p<0.001
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mAEA-treated group (Fig. 6j). Contrary to our prediction,
AM251-treated animals had lower plasma GIP and insulin
concentrations and correspondingly higher 30 min plasma
glucose levels after glucose gavage than their corresponding
control group (see electronic supplementary material [ESM]
Fig. 1). However, the plasma acetaminophen concentrations
indicated a significant slowing of gastric emptying in the
AM251-treated group, which would result in reduced glucose
delivery to the duodenal K cells. In the context of the resulting
smaller luminal glucose stimulus, it is not possible to interpret
whether endogenous cannabinoid levels affected glucose-
triggered GIP release.
Discussion
We demonstrate here that GIP release can be inhibited through
the recruitment of Gαi-coupled receptors. Most importantly,
CB1 receptor stimulation suppresses GIP but not GLP-1 se-
cretion. Expression of cannabinoid receptors has, to our
knowledge, not previously been reported in enteroendocrine
cells, yet our expression analysis identified the CB1 receptor
message (Cnr1) as one of the highest expressed G-protein-
coupled receptor mRNAs in FACS-purified K cells. Consis-
tent with this observation, GIP secretion was inhibited by the
CB1 receptor agonist mAEA in vitro, an effect partly reversed
by co-application of the inverse agonist AM251.
As expected, we observed a robust inhibition of both GIP
and GLP-1 secretion in vitro by somatostatin. A suppressive
effect of somatostatin on incretin secretion has long been
known. Consistent with the predominant Gαi coupling of
SSTRs, somatostatin suppressed cytosolic cAMP responses
in the GLUTag cell line, at least in part via SSTR5. A role
for SSTR5 in primary murine K and L cells was also evident
from secretion studies in primary intestinal cultures. Addi-
tional roles for SSTR2 and SSTR3 in both cell types are
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Fig. 5 Effects of CB1 ligands on K and L cells. (a) GIP secretion from
primary small intestinal cultures treated with IBMX (100 μmol/l),
mAEA (10 μmol/l) and AM251 (1 μmol/l), as indicated. (b, c) GLP-
1 secretion from primary small intestinal (b) and colonic (c) cultures
treated with IBMX (100 μmol/l), mAEA, (10 μmol/l) and AM251
(1 μmol/l), as indicated. In (a–c) Data are expressed relative to the
basal secretory rate measured in parallel on the same day. Data repre-
sent the means ± SEM of the number of wells indicated above each bar.
Statistical significance was assessed by one-way ANOVA with post
hoc Bonferroni test: **p<0.01, ***p<0.001 compared with control
buffer; ††p<0.01, †††p<0.001 between conditions as indicated. (d)
GLP-1 secretion from GLUTag cells treated with IBMX (100 μmol/l),
mAEA (10μmol/l) and AM251 (1 μmol/l), as indicated. GLP-1 secretion
is expressed relative to the basal secretion measured in parallel on the
same day. Data are means ± SEM of the number of wells indicated above
each bar. Statistical significance was assessed by one-way ANOVAwith
post hoc Bonferroni test: ***p<0.001 compared with control; ††p<0.01
between conditions. (e) GLUTag cells transfected with Epac2-camps
were perfused with forskolin (fsk; 2 μmol/l) with or without mAEA
(10 μmol/l), followed by fsk/IBMX (10 and 100 μmol/l respectively),
as indicated. CFP and YFP emission was monitored in response to
excitation with 435/10 nm. Three traces, each representing the CFP/
YFP ratio of a single cell, are shown. (f) Mean changes in the CFP/YFP
emission ratio in response to application of fsk, mAEA or AM251
(1 μmol/l), in experiments performed as in (e). Responses to fsk/mAEA,
fsk/mAEA/AM251 and the final application of fsk alone were normalised
to the response triggered by the first application of fsk in the same cell.
Data are means and error bars show 1 SEM with the number of cells
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by one-way ANOVA with post hoc Bonferroni test: **p<0.01, ***p<
0.001 compared with first application of fsk; †p<0.05 comparing the
mAEA response in the absence and presence of AM251
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suggested by the mRNA expression data and the incomplete
suppression of the inhibitory effect of somatostatin by the
SSTR5 antagonist. This is in agreement with a previous
report that GLP-1 secretion from fetal rat intestinal cultures
was suppressed by specific agonists of SSTRs in the rank
order SSTR5>SSTR 2>SSTR 3 [22].
Although we detected mRNA expression of Cnr1 in small
intestinal L cells, we observed no inhibition of GLP-1 secretion
from primary cultures by mAEA. The CB1-dependent inhibi-
tion of GIP but not GLP-1 release did not reflect interexperi-
mental variability as the difference was still observed when
supernatant fractions from the same wells were analysed for
both incretins. A lack of effect of mAEA on GLP-1 secretion
was also observed in colonic cultures, consistent with the
absence of Cnr1 expression in purified colonic L cells. We
thus conclude that the observed Cnr1 mRNA expression in
small intestinal L cells either does not translate into a sufficient
density of functional receptors or reflects only a minority of
L cells. In this context, it is interesting to note that there is an
established overlap in the small intestinal K and L cell popu-
lations, with up to 20% of L cells also expressing GIP [23–25].
Under in vitro conditions, the inverse CB1 agonist AM251
did not enhance basal or IBMX-triggered GIP secretion in the
absence of an exogenous CB1 receptor agonist. This indicates
that there is no significant constitutive activity of CB1 recep-
tors in K cells capable of overcoming a rise in cAMP in the
presence of phosphodiesterase inhibition. Interestingly, how-
ever, the SSTR5 antagonist also failed to enhance GIP secre-
tion from small intestinal cultures in the absence of added
somatostatin, despite the evident somatostatin tone in the same
cultures as demonstrated by the doubling of GLP-1 release
under the same conditions. Indeed, the measured somatostatin
concentration of approximately 50 pmol/l in supernatant frac-
tions from small intestinal cultures is close to the reported
affinity of rodent SSTR5 (Kd 50–300 pmol/l [26]). Endoge-
nously released somatostatin was also reported to block GIP
release in canine intestinal cultures enriched by elutriation for
endocrine cells [21]. As the SSTR5 antagonist was capable of
partially reversing the inhibition of GIP secretion by exoge-
nously applied somatostatin, it is possible that the observed
GIP secretion in the presence of IBMX represents a maximal
stimulation of K cells under our culture conditions.
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Fig. 6 Effects of CB1 ligands on hormone secretion in vivo. (a–c)
Plasma GIP levels in individual rats treated at −30 min with mAEA (a),
vehicle control (squares represent controls for mAEA, diamonds rep-
resent controls for AM251) (b), or AM251 (c). Samples at 0 min were
taken immediately prior to glucose gavage. (d–j) Plasma profiles for
GIP (d), GLP-1 (g), insulin (h), glucose (i) and acetaminophen (j), and
area under the curve (AUC) for GIP (e) or GLP-1 (f), following i.p.
administration of mAEA (black circles and black bars; n08) or vehicle
control (white squares and open bars; n05) at −30 min and glucose/
acetaminophen gavage at 0 min. Data are means ±1 SEM of the plasma
concentrations observed at the times indicated. Statistical significance
was assessed in (d) and (g–j) by two-way ANOVA with post hoc
Bonferroni test (**p<0.01 vs vehicle control) and in (e) and (f) by
unpaired Student’s t test (*p<0.05)
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The expression of Cnr1 and in vitro effects of CB1 ligands
on GIP release were reflected by our in vivo observations in
rats, which showed that GIP but not GLP-1 responses to an
OGTT were reduced by mAEA pretreatment. As endocanna-
binoids are known to inhibit gastric emptying [27], a trivial
explanation for the observed delayed appearance of GIP in the
plasma could have been a slowed transit of glucose into the
duodenum. This seems an unlikely explanation for our find-
ings, however, as we observed no significant differences in the
time courses of glucose, acetaminophen and GLP-1 appear-
ance in the plasma between the two groups. It thus appears
likely that direct CB1-dependent inhibition of K cells at least
in part underlies the reduction in the GIP response caused by
mAEA in vivo. In a similar experiment to determine the in
vivo effect of AM251, GIP levels were found to increase in
the fasting state, but it was not possible to assess endogenous
CB1 tone after a glucose challenge because AM251 unex-
pectedly slowed gastric emptying. This is likely to have re-
duced glucose delivery to the duodenal K cells, accounting for
the observed lower plasma GIP and insulin levels, and corre-
spondingly higher plasma glucose concentration at 30 min.
In the stomach and small intestine of rodents, arachidonyl-
ethanolamide and, in some but not all studies, the related
endocannabinoid 2-arachidonyl-glycerol have been reported
to increase in concentration upon fasting, with levels returning
to baseline within an hour of refeeding [28–30]. Intestinally
generated endocannabinoids are thought to exert orexigenic
effects by signalling through vagal afferent neurons to satiety
centres in the central nervous system (CNS) [27, 30]. The
stimulatory effect of systemic cannabinoids on feeding is,
however, believed to depend mostly on CB1 receptor activa-
tion in the CNS [31]. Rimonabant, an inverse agonist at the
CB1 receptor, was used clinically for the treatment of obesity
due to its anorectic effects, but was withdrawn from the
market because of psychological side effects, including de-
pression and increased suicidal thoughts [32].
Although most effects of rimonabant on feeding are mir-
rored in a mouse with CNS-restricted CB1 receptor knockout
[33], there is still considerable interest in developing drugs
targeting peripheral cannabinoid receptors for the treatment of
obesity [27, 31]. Our results suggest that an additional effect of
antagonising peripheral CB1 receptors may be to increase GIP
secretion. Although this may beneficially enhance the incretin
effect, GIP is thought to promote storage of energy resources in
peripheral tissues, possibly due to direct effects on adipocytes
[34, 35]. This would potentially oppose the beneficial effects of
CB1 receptor antagonism on body weight, although it should
be noted that the effect of GIP on nutrient storage is controver-
sial, with some laboratories reporting lipolytic actions on adi-
pocyte models in vitro [36]. Indeed, in humans, GIP had only
minor effects on triacylglycerol clearance that became evident
only under conditions of a hyperglycaemic hyperinsulinaemic
clamp [37].
The multiple roles of the endocannabinoid system, both
peripherally and centrally, have made CB1 a difficult recep-
tor to target successfully for the therapy of diabetes and
obesity [32]. Our results suggest that there is a small but
significant CB1-dependent inhibition of K cells during fast-
ing that might serve to increase the sensitivity to feeding-
related signals, as the postprandial reduction in endocanna-
binoid levels would activate K cells in concert with nutrient
stimuli arriving in the duodenal lumen. Regulation of GIP
secretion by the endocannabinoid system could be envis-
aged as part of the transition from a preprandial to a post-
prandial metabolic state. Although the rate of delivery of
glucose to the duodenum appears to provide a dominant
degree of control over K cell secretion, as evident from the
in vivo experiments with AM251, CB1 activation might
provide a useful tool to dissociate GIP and GLP-1 secretion.
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